Patent US5373095A successfully refreshed from Google Patents.
US5373095A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Steroid compounds
Assignee: Pharmacia and Upjohn Co
•
Filing: 1993-09-23
•
Granted: 1994-12-13
•
Expires: 2013-09-23
Abstract
Abstract Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.
Inventors
- 👤 Roy A. Johnson
- 👤 Gordon L. Bundy
- 👤 Gilbert A. Youngdale
- 👤 Douglas R. Morton
- 👤 Donald P. Wallach, deceased
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 05:32
CPC Classifications
C; C07; C07J; C07J51/00; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/36; C07D213/38; C07F; C07F9/00; C07F9/02; C07F9/06; C07F9/22; C07F9/224; C07F9/24; C07F9/2454; C07F9/2458; C07J41/00; C07J41/0005; C07J41/0033; C07J41/005; C07J41/0072; C07J43/00; C07J43/003
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
34 words
A compound selected from the group consisting of: N-(3-(dimethylamino)propyl)-N-methyl-3-(1-phenyl-5-tetrazoly)oxyestra-1,3,5(10)-trien-17β-amine; 17β-(1-(4-methyl)piperazinyl)-3-methoxyestra-1,3,5(10)-triene; 17β-(1-(4-methyl)piperazinyl)-3 -methoxyestra-2,5(10)-diene; N-(2-(N'-morpholino)ethyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine dihydrochloride; N-(3-(N'-morpholino)propyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine; N-(2-(2-morpholinoethyl)aminoethyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine trihydrochloride; 3-methoxy-N-(3-(pyrrolidin-2-on-1 -yl)propyl)estra-1,3,5(10)-trien-17β-amine acetate; N-(3-(imidazoyl)propyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine acetate; 3-methoxy-N-(2-(1-methylpyrrol-2-yl)ethyl)estra-1,3,5(10)-trien-17β-amine; N-(2-furfuryl)-3-methoxyestra-1,3,5(10)-trien-17β-amine; 3-methoxy-N-(2'-pyridinylmethyl)estra-1,3,5(10)-trien-17β-amine hydrochloride; 3-methoxy-N-({2-(N'-(5-nitro-2-pyridinyl)amino)ethyl)}estra-1,3,5(10)-trien-17βamine; N-(3-methoxy-1,3,5(10)-estratrien-17-yl)-1,4-bis(3-aminopropyl)piperazine; or a pharmacologically acceptable salt thereof.
Claim 2
Dependent Claim
34 words
A compound selected from the group consisting of: N-(3-(dimethylamino)propyl)-N-methyl-3-(1-phenyl-5-tetrazoly)oxyestra-1,3,5(10)-trien-17β-amine; 17β-(1-(4-methyl)piperazinyl)-3-methoxyestra-1,3,5(10)-triene; 17β-(1-(4-methyl)piperazinyl)-3 -methoxyestra-2,5(10)-diene; N-(2-(N'-morpholino)ethyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine dihydrochloride; N-(3-(N'-morpholino)propyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine; N-(2-(2-morpholinoethyl)aminoethyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine trihydrochloride; 3-methoxy-N-(3-(pyrrolidin-2-on-1 -yl)propyl)estra-1,3,5(10)-trien-17β-amine acetate; N-(3-(imidazoyl)propyl)-3-methoxyestra-1,3,5(10)-trien-17β-amine acetate; 3-methoxy-N-(2-(1-methylpyrrol-2-yl)ethyl)estra-1,3,5(10)-trien-17β-amine; N-(2-furfuryl)-3-methoxyestra-1,3,5(10)-trien-17β-amine; 3-methoxy-N-(2'-pyridinylmethyl)estra-1,3,5(10)-trien-17β-amine hydrochloride; 3-methoxy-N-({2-(N'-(5-nitro-2-pyridinyl)amino)ethyl)}estra-1,3,5(10)-trien-17βamine; N-(3-methoxy-1,3,5(10)-estratrien-17-yl)-1,4-bis(3-aminopropyl)piperazine; or a pharmacologically acceptable salt thereof.
Claim 3
Dependent Claim
18 words
A compound selected from the group consisting of: N-(3-methoxyestra-1,3,5(10)-trien-17-yl)-1-azetidinehexanamine; 1-(3-((17-((3-(dimethylamino)propyl)methylamino)estra-1,3,5(10)-trien-3-yl)oxy)propyl)-1H-pyrrole-2,5-dione; and hexahydro-4-(3-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)propyl)-2H-1,4-diazepin-2-one; or a pharmacologically acceptable salt thereof.
Claim 4
Dependent Claim
18 words
A compound selected from the group consisting of: N-(3-methoxyestra-1,3,5(10)-trien-17-yl)-1-azetidinehexanamine; 1-(3-((17-((3-(dimethylamino)propyl)methylamino)estra-1,3,5(10)-trien-3-yl)oxy)propyl)-1H-pyrrole-2,5-dione; and hexahydro-4-(3-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)propyl)-2H-1,4-diazepin-2-one; or a pharmacologically acceptable salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-12-12 | 1998-06-13 | 1998-12-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-12-12 | 2002-06-13 | 2002-12-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-12-12 | 2006-06-13 | 2006-12-13 | $7700.00 | Window Closed / Lapsed |